Shi Y, Li Y, Chen W, Zhang M, Qian D, Li T, Dai Y, Li G. Cost-effectiveness analysis of Sintilimab vs. Docetaxel as the second-line therapy of squamous non-small cell lung cancer in China. Health Decision. 2024;2(S1). doi:10.54844/hd.2024.0007